Lv11
78 积分 2025-06-24 加入
Mapping the effectiveness and risks of GLP-1 receptor agonists
1小时前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
15天前
已完结
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
2个月前
已完结
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
2个月前
已完结
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
2个月前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
2个月前
已完结
Health policy and public health implications of obesity in China
2个月前
已完结
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
2个月前
已完结
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
2个月前
已完结
Glucagon-like peptide-1 receptor agonists are associated with a lower risk of peptic ulcer disease: a nationwide cohort study
2个月前
已完结
皖公网安备34019202002308
